Luxeptinib

  Cat. No.:  DC46932  
Chemical Structure
1616428-23-9
For research use only. We do not sell to patients.
We match the best price and quality on market.
Email:order@dcchemicals.com  sales@dcchemicals.com
Tel:+86-021-58447131
We are official vendor of:
  • 20
  • 19
  • 18
  • 17
  • 16
  • 15
  • 14
  • 12
  • 11
  • 10
  • 9
  • 8
  • 13
  • 6
  • 5
  • 4
  • 3
  • 2
  • 1
More than 5000 active chemicals with high quality for research!
Field of application
Luxeptinib (CG-806) is an orally active, reversible, first-in-class, non-covalent and potent pan-FLT3/pan-BTK inhibitor. Luxeptinib induces cell cycle arrest, apoptosis or autophagy in acute myeloid leukemia cells.
Cas No.: 1616428-23-9
Chemical Name: Luxeptinib
Formula: C25H17F4N5O2
M.Wt: 495.43
Sotrage: 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO
MSDS
COA
LOT NO. DOWNLOAD
2018-0101
Cat. No. Product name Field of application
DC47657 LT-850-166 LT-850-166 is a potent FLT3 inhibitor with the capacity of overcoming a variety of FLT3 mutations.
DC46932 Luxeptinib Luxeptinib (CG-806) is an orally active, reversible, first-in-class, non-covalent and potent pan-FLT3/pan-BTK inhibitor. Luxeptinib induces cell cycle arrest, apoptosis or autophagy in acute myeloid leukemia cells.
DC44089 FLT3-IN-4 FLT3-IN-4 is a potent and orally effective Fms-like tyrosine receptor kinase 3 (FLT3; IC50=7 nM) inhibitor for treating acute myelogenous leukemia.
DC28136 Tandutinib hydrochloride Tandutinib hydrochloride (MLN518 hydrochloride) is a potent and selective inhibitor of the FLT3 with an IC50 of 0.22 μM, and also inhibits c-Kit and PDGFR with IC50s of 0.17 μM and 0.20 μM, respectively. Tandutinib hydrochloride can be used for acute myelogenous leukemia (AML). Tandutinib hydrochloride has the ability to cross the blood-brain barrier.
DC11780 FLT3-IN-5e FLT3-IN-5e is a nove potent, selective FLT3 inhibitor with Kd of 3.6 nM, IC50 of <6 nM.
DC10922 AAE871 AAE871 (AAE-871) is a potent type I kinase inhibitor of FLT3 with IC50 of 34 nM, potently inhibits proliferation of FLT3-ITD- and D835Y-expressing cells (IC50<10 nM) through selective inhibition of FLT3 kinase activity..
X